This is the article we built this entire site to write. If you're a man experiencing hair loss in 2026, this is your evidence-based roadmap — every proven treatment ranked by clinical data, with real costs and telehealth access information.
No sponsored rankings. No affiliate-driven bias. Just the science, organized so you can make an informed decision.
What's Covered
#1: Finasteride + Minoxidil Combination Therapy
Evidence grade: A (multiple RCTs) • Cost: $20–$55/month • Efficacy: Up to 94.1% show improvement
The combination of oral finasteride (1mg daily) and topical minoxidil (5%) is the gold standard. Finasteride blocks the conversion of testosterone to DHT — the hormone that miniaturizes hair follicles — while minoxidil stimulates blood flow and extends the growth phase. They work through completely different mechanisms, which is why combining them produces dramatically better results than either alone.
A landmark study showed that 94.1% of men using both treatments experienced improvement, compared to 80.5% for finasteride alone and 59% for minoxidil alone. The combination addresses hair loss from both sides: preventing further loss (finasteride) and stimulating regrowth (minoxidil).
How to access: Generic finasteride costs $8–$22/month from telehealth platforms. Topical minoxidil is $8–$15/month OTC. Hims offers a combination topical spray (0.3% finasteride + 6% minoxidil) starting at $35/month. Happy Head offers custom-compounded formulations from $49/month.
For a complete deep dive, see our finasteride and minoxidil combination guide and our finasteride beginner's guide.
#2: Oral Finasteride Alone
Evidence grade: A • Cost: $8–$22/month • Efficacy: 80–90% maintain or improve hair
If you only take one medication, this is the one. Oral finasteride 1mg daily reduces scalp DHT by approximately 64%, which is enough to halt further miniaturization in the vast majority of men. Clinical trials spanning over a decade show that 83% of men maintain their hair count at 10 years (vs. continued loss in controls).
Side effects: Sexual side effects (decreased libido, erectile changes) occur in 1–2% of men and are reversible upon discontinuation. The nocebo effect is well-documented — a key study found that men informed about potential side effects reported them at 43.6% vs 15.3% for uninformed men, with effects completely reversible within 5 days. See our finasteride side effects guide for the complete data.
Where to get it: Keeps from $8/month, Hims from $22/month, Ro from $15/month, or through Sesame Care for a provider consultation.
#3: Topical Minoxidil 5%
Evidence grade: A • Cost: $8–$30/month • Efficacy: ~50–60% show meaningful improvement
The only FDA-approved OTC treatment for hair loss. Minoxidil is a vasodilator that increases blood flow to the follicle and extends the anagen (growth) phase. It works best on the crown/vertex — effectiveness on the hairline is lower but still documented. Available as liquid (applied with dropper) or foam (dries faster, less irritation).
Key consideration: Results take 3–6 months to appear, and you'll likely experience a "dread shed" at weeks 2–8 as old hairs are pushed out to make room for new growth. This is a sign the medication is working. See our dread shed guide.
Pricing: Kirkland generic liquid ~$8/month (Amazon). Hims foam $15–$30/month. Rogaine foam $14–$17/month.
#4: Low-Dose Oral Minoxidil
Evidence grade: B (growing body of retrospective and prospective studies) • Cost: $15–$30/month • Efficacy: 80–90% response rate in published series
The off-label revolution. Low-dose oral minoxidil (1.25–5mg daily for men) has transformed dermatology practice. It avoids the scalp irritation and compliance issues of topical formulations while producing stronger systemic effects. Multiple large retrospective studies show response rates of 80–90% — significantly higher than topical application.
Important: Oral minoxidil requires medical supervision due to cardiovascular considerations (it was originally developed as a blood pressure medication). Side effects at low doses include hypertrichosis (body hair growth) in 15–20% and lower extremity edema in <5%. Baseline ECG is recommended. See our oral minoxidil guide and safety guide.
#5: Dutasteride (Off-Label)
Evidence grade: B • Cost: $15–$40/month • Efficacy: Superior to finasteride in head-to-head trials
Dutasteride blocks both type I and type II 5-alpha reductase (finasteride only blocks type II), reducing scalp DHT by over 90% versus ~64% with finasteride. A 2014 head-to-head RCT showed dutasteride 0.5mg outperformed finasteride 1mg in hair count increases at 24 weeks. It's FDA-approved for BPH but not for hair loss — hence the off-label ranking.
Trade-off: Stronger DHT suppression means potentially higher risk of sexual side effects (reported in 4–7% in trials). Its long half-life (~5 weeks vs ~6 hours for finasteride) means effects persist longer after discontinuation — for better or worse. See our dutasteride vs finasteride comparison.
#6: Low-Level Laser Therapy (LLLT)
Evidence grade: B- • Cost: $200–$800 (device) or $25–$50/session • Efficacy: Modest improvement as adjunct
FDA-cleared (not approved) laser devices deliver red or near-infrared light to the scalp, which may stimulate cellular metabolism in the follicle. A 12-month study showed 25% improvement in hair density with home helmet devices used three times weekly. LLLT is best used as an adjunct to pharmacological treatment, not as a standalone. Results are modest compared to finasteride or minoxidil.
#7: PRP (Platelet-Rich Plasma)
Evidence grade: B- (heterogeneous study quality) • Cost: $500–$2,000 per session, typically 3–4 sessions • Efficacy: Variable; best as adjunct
PRP involves drawing your blood, concentrating the platelets, and injecting the growth-factor-rich plasma into your scalp. Meta-analyses show positive effects on hair density and thickness, but study quality varies significantly and there's no standardized protocol. PRP is most useful as an add-on treatment for patients already on finasteride and minoxidil who want additional benefit. See our PRP and exosome guide for the complete evidence review.
What's Coming: The 2026–2029 Pipeline
The hair loss treatment landscape is undergoing its most dramatic transformation in three decades. Here are the most promising candidates:
Clascoterone 5% Topical Solution (Cosmo Pharmaceuticals)
Completed two Phase 3 trials (SCALP-1 and SCALP-2) across 1,465 men at 51 sites. SCALP-1 showed a 539% relative improvement in target-area hair count versus vehicle. The drug blocks androgen receptors directly at the follicle without systemic absorption — meaning no sexual side effects were reported. Regulatory submissions to the FDA and EMA are planned following completion of 12-month safety data in spring 2026. If approved, this would be the first new mechanism for AGA in over 30 years. See our clascoterone guide.
PP405 (Pelage Pharmaceuticals)
A topical gel targeting hair follicle stem cell metabolism — an entirely novel mechanism with no hormonal component. Phase 2a results in 78 patients showed 31% of men with advanced baldness gained more than 20% hair density within 8 weeks, versus 0% for placebo. Critically, PP405 stimulated new terminal (thick, visible) hair growth in previously bald areas — something no existing treatment reliably achieves. No systemic absorption detected. Backed by $120 million in Series B funding, Phase 3 trials are launching in 2026. See our drug pipeline article.
Deuruxolitinib (Leqselvi) — For Alopecia Areata
FDA-approved in 2024 for severe alopecia areata (autoimmune hair loss, not pattern baldness). MHRA approval followed in March 2026. In Phase 3 trials, approximately 30% of patients with severe AA achieved 80% or more scalp coverage after 24 weeks, with 65–70% showing significant regrowth. This is relevant for people with AA but does not treat androgenetic alopecia. See our JAK inhibitor guide.
Ready to Start Treatment?
A telehealth provider can evaluate your hair loss pattern, recommend the right treatment combination, and prescribe appropriate medications — all from home.
Book a Consultation — Sesame Care